|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proximagen's management team combines successful entrepreneurs with experienced leading-edge scientific experts and researchers.
- Chief Executive Officer
Kenneth Mulvany
Kenneth joined Proximagen in March 2004 as Chief Executive and acts to focus the Company's commitment to deliver novel drugs
and innovative new treatments for Central Nervous System disorders, bringing new hope to patients and value to shareholders.
Prior to joining Proximagen, Kenneth worked in the venture capital markets focused on the technology industry.
Kenneth played key roles in developing several successful high-tech start-ups. He brings 15 years of business leadership and experience to Proximagen.
Kenneth competed in the 1992 America's Cup.
- Finance Director
James Hunter
James joined Proximagen in January 2005 as Financial Controller and was subsequently appointed to the Board in February 2006. James joined the Group after spending six years in the corporate finance team at Ernst & Young where he worked in mergers and acquisitions and corporate restructuring. James has an MBA from the Cranfield School of Management.
- Head of Business Development
Dr Tim Sparey
Tim joined Proximagen in November 2009 from Merck-Serono where he held the role of Head of UK Business Development. Formerly he was a Director in Licensing & External Research, Europe at Merck and he was also a Research fellow in the Department of Medicinal Chemistry (Group Leader) at Merck, working in Alzheimer's disease, Schizophrenia, Parkinson's disease, anaesthetics and stem cell therapeutics.
- Head of Non-clinical Development
Bruce Campbell
Bruce joined Proximagen in 2004 from Neurocrine, the NASDAQ listed biotechnology company. Bruce was Senior VP of Development at Neurocine and since 1998 he had overall responsibility for directing Neurocrine's selection and advancement of drug candidates from research into clinical development. This culminated in advancing eight novel drugs into clinical trials
Bruce has been a Director and European Chairman of the Drug Information Association, a member of the European ICH Safety Working Party and secretary of the Society for Pharmaceutical Medicine.
- Senior Scientific Consultant
Professor Peter Jenner
Peter is a key opinion leader in the field of Parkinson's disease.
Peter is a Professor of Pharmacology in the Guy's, King's St Thomas' School of Biomedical Sciences at King's College London. He is the head of the Neurodegenerative Diseases Research Group and a Director of the National Parkinson Foundation Centre of Excellence. In particular, he has contributed to understanding mechanisms involved in the initiation and progression of nigral cell death in Parkinson's disease.
Professor Jenner has published more than 800 papers. He is a frequent speaker at international congresses and to lay groups of patients and caregivers.
|
|
|
|
|
|
|
